Memorial Hospital Research Laboratories
The Luke Pike Lab
Research

The Luke Pike Lab seeks to understand the unique biology of brain metastasis (BM) to improve outcomes for patients afflicted with various solid tumors. BM is exceptionally common, with an estimated 400,000 patients diagnosed yearly in the U.S. The mechanisms by which cancer cells spread to and survive in the brain are poorly understood. The standard treatment for BM has been radiation therapy with or without surgical resection, as most drug therapies are ineffective against BM. New drugs, such as immune checkpoint or targeted inhibitors, have shown promising activity against BM, but our understanding of why they often fail in the brain is incomplete. The Pike Lab uses cutting-edge molecular techniques to understand tumor tropism for the brain and to identify features of human BM that might lead to drug or radiation resistance and the survival of cancer cells in the brain tumor microenvironment.

Publications
People

Luke Pike, MD, DPhil
- Physician-scientist Luke R.G. Pike studies the mechanistic underpinnings of brain metastasis and seeks to identify translational correlates with outcomes following local or systemic therapy.
- DPhil/PhD, Medical Oncology, University of Oxford
- MD, Yale School of Medicine
- [email protected]
- Email Address
- View physician profile
- Physician profile
Members

- BS, Yale University















Resident Physician, Memorial Sloan Kettering Cancer Center, New York, NY

Memorial Sloan Kettering RO PGY3

Intern

Medical College of Georgia MS3

Project Coordinator

Cornell MS3

Memorial Sloan Kettering RO PGY3

Brown MS2

Undergraduate, University of Miami

Memorial Sloan Kettering RO PGY5

Memorial Sloan Kettering RO PGY4

Harvard Radiation Oncology Program, PGY3

Albert Einstein MS3
Yale Undergrad

Pennsylvania State College of Medicine MS3

Memorial Sloan Kettering RO PGY5
Memorial Sloan Kettering PGY1
Lab Alumni
Memorial Sloan Kettering RO PGY3
Lab Affiliations
Achievements
- Alexander Graham Bell PhD Scholarship (2009)
- The Rhodes Scholarship (2007)
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Luke Pike discloses the following relationships and financial interests:
-
Clovis Oncology
Equity -
Monograph Capital Advisors, L.P.
Professional Services and Activities
-
Monte Rosa Therapeutics, Inc.
Professional Services and Activities -
Turnstone Biologics Corp.
Professional Services and Activities
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].